Pramipexole: A nonergot dopamine agonist as drug therapy in Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 1, Issue 1, 2001, Pages 43-51

  Hubble, Jean P ^a   Novak, Peter ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Dopamine agonist; Motor Fluctuation; Parkinson's disease; Pramipexole

Indexed keywords

AMINOBENZOTHIAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; UNCLASSIFIED DRUG;

ADD ON THERAPY; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; POSTMARKETING SURVEILLANCE; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT;

EID: 0035741351     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.1.1.43     Document Type: Review

References (29)

1. Epidemiology of Parkinson's disease
2. Aromatic aminoacids and modification of parkinsonism
3. Success and problems of long-term levodopa therapy in Parkinson's disease
4. Motor complications associated with chronic levodopa therapy in Parkinson's disease
5. Levodopa motor complications in Parkinson's disease
6. 2 receptor agonist
7. Steady-state pharmakokinetic properties of pramipexole in healthy volunteers
8. Pramipexole in patients with early Parkinson's disease
9. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study
10. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
11. Pramipexole vs. levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
12. Decreased SPECT [I-123] β-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease
13. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity
14. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice
15. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
16. The use of pramipexole, a novel dopamine agonist (DA), in advanced Parkinson's disease
17. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
18. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
19. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double-blind, placebo-controlled, randomized, multicentre study
20. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease
21. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
22. A review of normal sleep and its disturbances in Parkinson's disease
23. Sleep attacks and Parkinson's disease treatment
24. Comparison of pramipexole, fluoxetine and placebo in patients with major depression
25. Double-blind, placebo-controlled trial of pramipexole in Progressive Supranuclear Palsy (PSP)
26. Clinical polysomnographic and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria
27. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures
28. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells
29. Preclinical studies of pramipexole: Clinical relevance. Review